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Adult T cell Leukaemia Lymphoma [ATL] is a mature
T cell neoplasm affecting 2 - 6% of HTLV-1 infected sub-
jects. ATL have been classified into 4 subtypes- smoulder-
ing, chronic leukaemia, acute leukaemia and lymphoma
subtype. First line treatment with zidovudine (ZDV) and
interferon-a (IFN) is recommended for smouldering,
acute and chronic leukaemia whilst for lymphoma subtype
combination chemotherapy is supplemented with ZDV/
IFN. However a substantial proportion of patients do not
respond or suffer treatment limiting side effects. Hence
there is an urgent need for novel treatment options.
Anti-CD25 in combination with bortezomib trialled in a
murine ATLL model out performed either agent alone.
We report 2 patients with Chronic ATL who were treated
with a novel combination of humanized anti-CD25 anti-
body, Basiliximab and proteosome inhibitor, Bortezomib.
Both patients had CD4+CD25+CCR4+CD127-lo ATL
phenotype, were Interferon Regulatory Factor-4 negative
and had responded to ZDV/IFN but had treatment limit-
ing side effect. Prior to the novel combination baseline
lymphocyte counts were 73.5 & 7.1 X 109/L, LDH 398 &
410 IU/L, CD4+CD25+ 97 & 97 % respectively. One
patient had disseminated cutaneous lymphoma. Treatment
was initially well tolerated and complete haematological
remission was achieved after 8-14 weeks but flow cytome-
try revealed persistence of cells with the aforementioned
ATLL phenotype. Discontinuation of Bortezomib in one
patient, due to neuropathy, was associated with an
immediate increase in CD4 counts. These early data
suggest that this combination presents a new targeted
therapy option for remission induction in treatment intol-
erant patients esp. leukemic subtype and warrant further
clinical investigation.
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